Managing AML: Staying on Track in a Rapidly Changing Treatment Landscape
Release Date: September 9, 2020
Expiration Date: September 9, 2021
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
There have been many advances to improve patient outcomes in AML, however, this can be challenging for clinicians to stay abreast of the fast pace of developments in treatment. In this activity, three experts cover novel targeted therapies for AML in both the frontline and relapsed/refractory setting, the role of mutational profiling in individualizing treatment, and emerging approaches with the potential to shape the current treatment landscape. This program will conclude with three unique case presentations as the experts share their insights to treatment selection.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.
Upon completion of this educational activity, participants should be able to:
- Summarize best practice strategies in molecular and mutational analysis in AML which assist in developing a patient-centered treatment approach
- Improve knowledge of new and emerging evidence in maintenance therapy as a new standard of care in AML
- Outline guidelines and clinical trial evidence to identify appropriate treatment approaches for patients with AML
- Describe strategies for identifying and managing treatment including dosing, and management of toxicities associated with novel and emerging therapies in AML
Chapter 1 - Overview of the AML Treatment Landscape – Naval Daver, MD - Chair
Chapter 2 - Progress and Challenges in Frontline Treatment – Courtney D. DiNardo, MD, MSCE
Chapter 3 - Molecular and Immunotherapies: Moving the Bar in Relapsed/Refractory AML – Eunice S. Wang, MD
Chapter 4 - Case Library: The Art and Science of Treatment Selection – Naval Daver, MD – Chair; Courtney D. DiNardo, MD, MSCE; Eunice S. Wang, MD
Instructions for Participation and Credit
This activity is eligible for credit through September 9, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Naval Daver, MD – Chair
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Dr. Naval Daver received his medical degree from Grant Medical College and Sir JJ Group of Hospitals, Mumbai, India, followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine in Houston, Texas. He is an Associate Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
A clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis, Dr. Daver is the co/principal investigator for more than 25 ongoing clinical trials in these diseases. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune and cytotoxic agents, and identifying and overcoming mechanism of resistance. He is especially interested in developing immune checkpoint- and vaccine-based approaches in AML, myelodysplastic syndromes (MDS), and myelofibrosis, and is conducting a number of these trials. Dr. Daver has published more than 100 peer-reviewed manuscripts. He has also authored numerous abstracts at national and international conferences.
Courtney D. DiNardo, MD, MSCE
Associate Professor of Medicine
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Dr. Courtney DiNardo received her medical degree from the University of Michigan, Ann Arbor. She completed her internal medicine internship and residency, followed by a hematology/oncology fellowship at the University of Pennsylvania. Dr. DiNardo is currently Associate Professor of Medicine in the Department of Leukemia, Division of Cancer Medicine, and Institutional Review Board Vice Chair at The University of Texas MD Anderson Cancer Center in Houston, Texas.
Dr. DiNardo’s clinical research focuses on prognostication and personalized therapeutics in myeloid malignancies. She is primary investigator of multiple novel IDH1/IDH2-targeted therapeutic agents currently in clinical trials and is also involved in the clinical development of venetoclax in combination with hypomethylating agent therapy for the treatment of newly diagnosed elderly AML. Her clinical and research focus on hereditary cancer predisposition syndromes led to development of the MD Anderson Hereditary Hematologic Malignancy Clinic, which provides clinical and research-based evaluation of underlying cancer predispositions and hereditary cancer syndromes in leukemia patients.
Eunice S. Wang, MD
Chief, Clinical Leukemia Service
Professor, Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Dr. Eunice Wang earned her medical degree from the Keck (University of Southern California) School of Medicine. She completed her internship and residency in internal medicine at Yale-New Haven Hospital, followed by clinical and research fellowships in hematology-oncology at Memorial Sloan Kettering Cancer Center in New York. She is Chief of the Leukemia Service and Professor of Oncology in the Department of Medicine at Roswell Park Comprehensive Cancer Center, Buffalo, New York. She is also an Associate Professor in the Department of Medicine, School of Medicine of Biomedical Sciences at the State University of New York at Buffalo (SUNY-UB).
Dr. Wang is a member of several professional organizations including the American Society of Hematology and the American Society of Clinical Oncology. She serves on the National Comprehensive Cancer Network (NCCN) Clinical Practice treatment guidelines panels for acute myeloid and acute lymphocytic leukemia. She is a prior recipient of a NIH Cancer Clinical Investigator Team Leadership Award (CCITLA) and a Mentored Research Scholar award from the American Cancer Society. Dr. Wang has authored/co-authored more than 90 peer-reviewed articles in the field of hematological malignancies. She maintains an active clinical practice with a portfolio of early phase clinical trials in acute leukemias and myeloid malignancies. She also leads a translational laboratory focused on preclinical studies of novel agents targeting the marrow microenvironment and immune responses.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by educational grant from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-033-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-033-128
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Naval Daver has received honoraria related to formal advisory activities and as a consultant from AbbVie Inc., Agios, Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation – A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Karyopharm Therapeutics, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and Sunesis. He has received grant support related to research activities from AbbVie, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Inc., GlycoMimetics, Inc., ImmunoGen, Incyte, Karyopharm, Nohla Therapeutics, Novartis, Pfizer, SERVIER, and Sunesis.
Dr. Courtney DiNardo has received honoraria as a consultant from AbbVie Inc., Agios, Celgene Corporation – A Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Immune-Onc Therapeutics, Inc., Novartis AG, and Takeda Oncology. She has received grant support related to research activities from AbbVie, Agios, Celgene Corporation – A Bristol-Myers Squibb Company, Calithera BioSciences, Inc., Daiichi Sankyo, and Immune-Onc. She has also disclosed a financial relationship with Notable.
Dr. Eunice Wang has received honoraria related to formal advisory activities from AbbVie Inc., Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Jazz Pharmaceuticals plc, Kite Pharma, MacroGenics, Inc., Pfizer Inc., and PTC Therapeutics, as well as speakers’ bureau activities from DAVA Oncology, Pfizer, and Stemline Therapeutics, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
- Chapter 1: Overview of AML; Progress and Challenges in Frontline Treatment – Run Time: 14:08
- Chapter 2: Molecular and Immunotherapies: Moving the Bar in Relapsed/Refractory AML – Run Time: 12:46
- Chapter 3: The Art and Science of Treatment Selection: Case Study Gallery – Run Time: 35:19
- Assessment and Evaluation